RT Journal Article
SR Electronic
T1 Effect of the p38 kinase inhibitor, SB 203580, on sephadex induced airway inflammation in the rat
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 947
OP 950
DO 10.1183/09031936.00.16594700
VO 16
IS 5
A1 M Birrell
A1 D Hele
A1 K McCluskie
A1 S Webber
A1 M Foster
A1 MG Belvisi
YR 2000
UL http://erj.ersjournals.com/content/16/5/947.abstract
AB SB 203580 is a pyridinyl imidazole compound which inhibits the release of pro-inflammatory cytokines, such as tumour necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta), in vitro and in vivo by inhibiting p38 mitogen-activated protein kinase (MAPK). The present study investigated the effects of SB 203580 in a model of airway inflammation induced by the topical administration of Sephadex into the rat airways. This inflammatory response is characterized by the development of lung oedema, airway tissue inflammatory cell recruitment and an increase in lung TNF-alpha and IL-1beta levels. Sephadex-induced lung oedema was accompanied by a significant increase in lung tissue TNF-alpha but not IL-1beta levels. There was also a significant increase in lung tissue macrophages and an increase in eosinophils which did not reach significance. SB 203580 administration significantly inhibited lung oedema (ED50=18 mg x kg(-1)) in a dose-related manner but was without significant effect on lung tissue cell recruitment or cytokine levels. These data suggest that the increase in tumour necrosis factor-alpha and lung oedema are separate processes which both contribute to Sephadex pathology. Furthermore, the inhibitory effect of SB 203580 on Sephadex-induced lung oedema suggests that p38 kinase inhibitors may be of use in pulmonary pathologies in which lung oedema is a feature.